Member Info for nursesteve

CC discussing FAP-Exd (AVA6103) - The profile of this second pre|CISION medicine in the preclinical setting is tremendous. The sustained release mechanism developed by Avacta scientists results in a robust concentration of active drug in the tumor over five days with the disappearance from the bloodstream in only two hours. This is the exact profile needed to achieve better efficacy with this highly potent topo I inhibitor. Could payoff for LTH be this year?

Biotech rarely follows a normal path. The only constant is good technology ends up with partnerships under buyouts. Avacta has a clear strategy, which it's executing, and have shown in the clinic that the tech does what it was designed it to do

Thanks slam dunk let’s hope your name says it all too 🤞

Hi all can you please provide your best guess of when we might see a decent RNS (that boosts the share price) and what it might contain?

Thanks GLA

One of these mornings we might get an RNS that starts with “Statement regarding possible offer” 🤔

Things will definitely become clearer over the first half of this new year. Let’s hope for a Happy and prosperous one GLA

Pleased with my earlier top up as should anyone else buying during the earlier dip. Now going to sit tight and ride out any further volatility while awaiting the successful outcome that the excellent science should bring. Hopefully we find out soon exactly what has been keeping Simon so busy 🤔 GLALTH’s

Well said WengerOut

It may well drop further but I’ve chosen to add 12631 more shares. Can’t see Richard and his chums being happy below 60p GLA

It ending that the share price now looks more like dropping below 60p when we were just anticipating a rise above £1 GLALTH’s not quite the holy grail yet is seems 🤔

The sustained release mechanism developed by Avacta scientists results in a robust concentration of active drug in the tumor over five days with the disappearance from the bloodstream in only two hours. This is the exact profile needed to achieve better efficacy with this highly potent topo I inhibitor. Certainly sounds very promising, only pre-clinical though so could also be viewed as another can kick down the Road? Nice to have the double whammy RNS even better if another comes tomorrow 🤞I’m hoping they announce FDA early approval for SGC let’s get some revenue earning products approved. That will Truely be pivotal! GLALTH’s

“This supports a broad market opportunity for all pre|CISION® medicines across our pipeline." That will do for me!

My question was about accelerated approval and I assumed the data would support this. That could be the next RNS but only if Avacta apply for it.

Music to my ears! 🎶 GLA

I’m certainly bracing myself as I’ve also got a dental appointment tomorrow! 😜

Still making a substantial loss each year. It will take many years to break even with this rate of sales. Unless something remarkable happens like a takeover? Why stay invested? Time to cut losses. Good luck to all shareholders brave enough to stay invested. I do think the company has some unique IP but it’s failing to significantly monetise it. I sold before the results and I’ll keep an eye on it 👋

Maybe they say based on the data the FDA has granted early approval for AVA6000 to be used for SGC? (Then this could also be used off licence?) - Depends if Chris and Richard are working towards maximising the company’s overall value or happy to take the low hanging fruit improved data at this stage could unlock?

In Oct the company reported salivary gland cancer with PFS follow up suggesting a more than doubling of the benchmark PFS and a disease control rate of 91%. I think we could see early approval alongside the results next week. Certainly seems to like it should meet the criteria for it! GLA

Could be the catalyst for AA? 20 Oct RNS - Median progression free survival (PFS) has not been reached in the cohort of patients with salivary gland cancer with PFS follow up suggesting a more than doubling of the benchmark PFS and a disease control rate of 91%

No maximum tolerated dose reached despite dosing up to 385 mg/m² (approximately 4x conventional doxorubicin dose) with no severe cardiac toxicity observed even at cumulative doses up to 550 mg/m²

Giving time to load up ?

Be interesting to see what the record sales figures are for the six months mentioned 🤔

I’m an investor & long term holder. I’d be interested in what those invested here think will be in the RNS’s we might receive before the end of this year - Q4 2025

Although it might be taken as a negative - I’m also interested in why we doing seem to have any TR1’s?